Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

SVB Leerink ups Aclaris Therapeutics to OP; PT to $3.50 from $1.50

SVB Leerink upgraded Aclaris Therapeutics (NASDAQ:ACRS) to “outperform” from “market perform” and raised its price target to $3.50 from $1.50, citing a new focus at the company. The stock closed at $1.41 on Oct. 21...

October 22, 2019

Developments

Titan Pharma to present two Probuphine posters at conference

Titan Pharmaceuticals (NASDAQ:TTNP) will present two posters on its buprenorphine implant, Probuphine, at the tenth American Conference of Pharmacometrics. Probuphine is a subdermal implant that provides six-month...

October 22, 2019

Developments

FDA accepts IntelGenx NDA resubmission for RIZAPORT

The FDA accepted IntelGenx’s (TSXV:IGX; OTCQX:IGXT) 505(b)(2) NDA resubmission for RIZAPORT VersaFilm for the treatment of acute migraines. The FDA also assigned a PDUFA goal date for completion of the NDA review of...

October 22, 2019

Developments

Zenabis cultivation output of dried cannabis up 21.8% in September

Zenabis Global’s (TSX:ZENA) cultivation output of dried cannabis reached 2,089 kg in September 2019, or 21.2% greater than its revised forecast output of 1,731 kg. Output at the company’s Zenabis Atholville plant...

October 21, 2019

Markets

HCW starts Dynavax Technologies at buy; PT $13

H.C. Wainwright initiated coverage of Dynavax Technologies (NASDAQ:DVAX) with a “buy” rating and $13 price target based on an outlook for the sales growth of the company’s marketed hepatitis B vaccine, Heplisav-B. The...

October 18, 2019

Developments

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 data from experimental models of fibrosis and non-alcoholic steatohepatitis (NASH) have been published in the peer-reviewed Journal of Pharmacology and Experimental...

October 16, 2019

Markets

Dawson James starts Dyadic at buy; PT $14

Dawson James Securities launched coverage of Dyadic International (NASDAQ:DYAI) with a “buy” rating and $14 price target. The stock closed at $6.66 on Oct. 15. Dyadic has been developing a gene expression platform over...

October 16, 2019

Developments

Kane Biotech, Dechra Veterinary expand license and distribution agreement to include South America

Kane Biotech (TSXV:KNE) and Dechra Veterinary Products, a unit of Dechra Pharmaceuticals (LSE:DPH), expanded their 10-year exclusive license and distribution agreement to include South America. The agreement was...

October 16, 2019

Markets

Stifel starts IGM Biosciences at buy; PT $32

Stifel launched coverage of IGM Biosciences (NASDAQ:IGMS) with a “buy” rating and $32 price target. The stock closed at $17.25 on Oct. 11. “We believe the company’s first/only-in-class, IgM-based antibody platform...

October 14, 2019

Developments

Immunic completes enrollment for Phase 2 MS trial

Immunic (NASDAQ:IMUX) completed enrollment for its Phase 2 trial assessing IMU-838 for the treatment of relapsing-remitting multiple sclerosis (RRMS). IMU-838 is a selective immune modulator that blocks the enzyme...

October 11, 2019

SVB Leerink ups Aclaris Therapeutics to OP; PT to $3.50 from $1.50

Titan Pharma to present two Probuphine posters at conference

FDA accepts IntelGenx NDA resubmission for RIZAPORT

Zenabis cultivation output of dried cannabis up 21.8% in September

HCW starts Dynavax Technologies at buy; PT $13

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Dawson James starts Dyadic at buy; PT $14

Kane Biotech, Dechra Veterinary expand license and distribution agreement to include South America

Stifel starts IGM Biosciences at buy; PT $32

Immunic completes enrollment for Phase 2 MS trial

Follow Us

Subscribe

General

More

Subscribe